• LAST PRICE
    3.3210
  • TODAY'S CHANGE (%)
    Trending Up0.1210 (3.7813%)
  • Bid / Lots
    3.3800/ 1
  • Ask / Lots
    3.5200/ 1
  • Open / Previous Close
    3.3500 / 3.2000
  • Day Range
    Low 3.2001
    High 3.5900
  • 52 Week Range
    Low 1.8000
    High 5.9000
  • Volume
    42,226
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 3.2
TimeVolumeGENE
09:32 ET6913.35
09:36 ET4003.35
09:45 ET15003.4022
09:48 ET28453.45
09:50 ET102873.48
09:54 ET2003.47
09:56 ET20003.3899
09:57 ET8113.36
10:01 ET25413.3001
10:03 ET3883.33
10:10 ET3453.335
10:12 ET25743.3
10:15 ET4003.3
10:21 ET20703.21
10:24 ET20783.33
10:28 ET2003.2702
10:37 ET4003.27
10:39 ET9803.3242
11:06 ET5003.25
11:18 ET10003.3099
11:20 ET16203.255
12:02 ET1003.29
12:23 ET1003.325
12:27 ET1503.28
12:57 ET1003.285
01:44 ET2003.335
02:09 ET9003.34
02:15 ET1003.35
02:22 ET1003.34
03:36 ET1473.34
03:38 ET2853.37
03:39 ET6003.3492
03:41 ET5003.35
03:43 ET2503.37
03:50 ET3023.3205
03:54 ET4003.321
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGENE
Genetic Technologies Ltd
12.0M
-2.9x
---
United StatesPFHO
Pacific Health Care Organization Inc
7.9M
15.8x
+17.15%
United StatesSYRA
Syra Health Corp
8.9M
-2.6x
---
United StatesMGRX
Mangoceuticals Inc
6.4M
-0.4x
---
United StatesNIVF
NewGenIvf Group Ltd
9.3M
-4.3x
---
United StatesBICX
BioCorRx Inc
10.0M
-3.3x
---
As of 2024-04-12

Company Information

Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor

Contact Information

Headquarters
60-66 Hanover St, FitzroyMELBOURNE, VIC, Australia 3065
Phone
---
Fax
---

Executives

Non-Executive Independent Chairman of the Board
Peter Rubinstein
Chief Executive Officer
Simon Morriss
Chief Financial Officer, Company Secretary
Kathryn Andrews
Chief Executive Officer - EasyDNA
Kevin Camilleri
Chief Scientific Officer
Richard Allman

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$12.0M
Revenue (TTM)
$5.5M
Shares Outstanding
3.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.16
EPS
$-1.15
Book Value
$0.09
P/E Ratio
-2.9x
Price/Sales (TTM)
2.2
Price/Cash Flow (TTM)
---
Operating Margin
-152.21%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.